|
|
Based on our research challenges currently exist with implementation of long
acting injectable therapy, (LAT). With the recently approved LAT Atypical
Antipsychotics we feel that PROMENTIS offers a series of fee for service offerings
that drive product awareness at the provider level and assist in the product
adoption for this pivotal therapy for your patients. PROMENTIS offers turn
key clinical solutions, education at live meetings, Webex clinical support
and value added on line publications. We think that there is consensus that
these LAT's will play an important role in the care of your patients but we
also realize their are challenges not exclusive to your practice but extend
throughout the country and exist on a national basis. PROMENTIS views the
following hurdles and solutions to be applicable to your practice on a regional
and national platform:
Obstacle: Clinics lack of infrastructure to properly buy, administer and bill
long acting injectables
Solution: PROMENTIS provides target practices specific solutions designed
to assist them with the implementation of long acting therapy clinical programing,
product acquisition, administration, billing, and reimbursement of Ivega Sustenna